| NCT05892614 | Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) | RECRUITING | PHASE2 | 2023-10-26 | 2026-04 | 2026-04 |
| NCT05415137 | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-09-15 | 2025-08-31 | 2025-07-31 |
| NCT04412668 | Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19 | COMPLETED | PHASE2 | 2020-06-04 | 2020-10-23 | 2020-10-23 |
| NCT03824392 | Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis | COMPLETED | PHASE1, PHASE2 | 2019-01-29 | 2021-06-29 | 2021-06-29 |
| NCT02836418 | Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED | PHASE1, PHASE2 | 2016-07-13 | 2017-04-18 | 2017-04-18 |
| NCT02603562 | Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy | COMPLETED | PHASE1, PHASE2 | 2016-03-30 | 2016-12-12 | 2016-12-12 |
| NCT02579239 | Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED | PHASE1, PHASE2 | 2015-11-30 | 2016-10-05 | 2016-10-05 |
| NCT02531217 | Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension | COMPLETED | PHASE1, PHASE2 | 2015-08-13 | 2016-05-26 | 2016-05-26 |
| NCT02239224 | Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy | COMPLETED | PHASE1, PHASE2 | 2014-09-04 | 2015-12-14 | 2015-12-14 |